590 related articles for article (PubMed ID: 28208215)
1. Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma.
de la Puente P; Azab AK
Eur J Haematol; 2017 Jun; 98(6):529-541. PubMed ID: 28208215
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
4. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
5. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy.
Pridgen EM; Langer R; Farokhzad OC
Nanomedicine (Lond); 2007 Oct; 2(5):669-80. PubMed ID: 17976029
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicine for Treatment of Lung Cancer.
Hussain S
Adv Exp Med Biol; 2016; 890():137-47. PubMed ID: 26703803
[TBL] [Abstract][Full Text] [Related]
7. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
8. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
de la Puente P; Luderer MJ; Federico C; Jin A; Gilson RC; Egbulefu C; Alhallak K; Shah S; Muz B; Sun J; King J; Kohnen D; Salama NN; Achilefu S; Vij R; Azab AK
J Control Release; 2018 Jan; 270():158-176. PubMed ID: 29196043
[TBL] [Abstract][Full Text] [Related]
9. Actively Targeted Nanoparticles for Drug Delivery to Tumor.
Bi Y; Hao F; Yan G; Teng L; Lee RJ; Xie J
Curr Drug Metab; 2016; 17(8):763-782. PubMed ID: 27335116
[TBL] [Abstract][Full Text] [Related]
10. New Strategies in Cancer Nanomedicine.
Tong R; Kohane DS
Annu Rev Pharmacol Toxicol; 2016; 56():41-57. PubMed ID: 26514197
[TBL] [Abstract][Full Text] [Related]
11. Inorganic nanoparticles: A potential cancer therapy for human welfare.
Pugazhendhi A; Edison TNJI; Karuppusamy I; Kathirvel B
Int J Pharm; 2018 Mar; 539(1-2):104-111. PubMed ID: 29366941
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems Against Cancer and Role of Tumor Microenvironment.
Ashfaq UA; Riaz M; Yasmeen E; Yousaf MZ
Crit Rev Ther Drug Carrier Syst; 2017; 34(4):317-353. PubMed ID: 29199588
[TBL] [Abstract][Full Text] [Related]
13. Update on current and potential nanoparticle cancer therapies.
Rink JS; Plebanek MP; Tripathy S; Thaxton CS
Curr Opin Oncol; 2013 Nov; 25(6):646-51. PubMed ID: 24097107
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in "smart" delivery systems for extended drug release in cancer therapy.
Kalaydina RV; Bajwa K; Qorri B; Decarlo A; Szewczuk MR
Int J Nanomedicine; 2018; 13():4727-4745. PubMed ID: 30154657
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
17. Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy.
Yang M; Chen Y; Zhu L; You L; Tong H; Meng H; Sheng J; Jin J
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254683
[TBL] [Abstract][Full Text] [Related]
18. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles' interactions with vasculature in diseases.
Tee JK; Yip LX; Tan ES; Santitewagun S; Prasath A; Ke PC; Ho HK; Leong DT
Chem Soc Rev; 2019 Oct; 48(21):5381-5407. PubMed ID: 31495856
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles and targeted drug delivery in cancer therapy.
Bahrami B; Hojjat-Farsangi M; Mohammadi H; Anvari E; Ghalamfarsa G; Yousefi M; Jadidi-Niaragh F
Immunol Lett; 2017 Oct; 190():64-83. PubMed ID: 28760499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
